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NRH:Quinone Oxidoreductase 2 (NQO2) has been described as having no enzymatic activity with nicotinamide adenine
dinucleotide (NADH) or NADPH as electron donating cosubstrates. Mitomycin C (MMC) is both a substrate for and a mechanistic
inhibitor of the NQO2 homologue NQO1. NRH:quinone oxidoreductase 2 catalysed the reduction of MMC at pH 5.8 with NADH
as a co-factor. This reaction results in species that inhibit the NQO2-mediated metabolism of CB1954. In addition, MMC caused an
increase in DNA cross-links in a cell line transfected to overexpress NQO2 to an extent comparable to that observed with an
isogenic NQO1-expressing cell line. These data indicate that NQO2 may contribute to the metabolism of MMC to cytotoxic species.
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Mitomycin c (MMC) is an anticancer antibiotic used in the
treatment of superficial bladder cancer and other tumours. As a
prodrug, the parent compound is relatively nontoxic compared to
the highly electrophilic metabolites formed following sequential or
simultaneous two electron reduction of the quinone to the
hydroquinone (Iyer and Szybalski, 1963). Many enzymes have
been implicated in the catalysis of MMC including NQO1 (Siegel
et al, 1992) and interest in NQO1-directed cancer chemotherapy
arose following the observation that NQO1 is more highly
expressed in tumour tissue when compared with matched healthy
tissue, for example lung (Schlager and Powis, 1990).
Evidence supporting NQO1 as a candidate enzyme in the
reduction of MMC has been reported. Isogenic cell line models
transformed into a high NQO1 phenotype are more sensitive than
parental cell lines to MMC (Mikami et al, 1996). A correlation
between MMC GI50 and NQO1 activity in the National Cancer
Institute 60 cell line panel presented evidence of a more
heterogeneous nature that NQO1 has a role in MMC bio-activation
(Fitzsimmons et al, 1996). Although MMC has been demonstrated
to be a substrate for NQO1, a large amount of enzyme and an
acidic pH are needed to see a reaction, indicating that MMC is a
poor substrate for NQO1 (Siegel et al, 1992). An added level of
complexity is that, when activated, MMC alkylates NQO1,
irreversibly inhibiting the enzyme (Siegel et al, 1993). Other
studies have failed to identify an association between sensitivity to
MMC and NQO1 activity (Robertson et al, 1992) and other
enzymes have been implicated in the bioreductive activation of
MMC including NADPH Cytochrome C reductase (Pan et al, 1984)
and nicotinamide adenine dinucleotide (NADH) cytochrome b5
reductase (Hodnick and Sartorelli, 1993). However, the one
electron reductases implicated in MMC activation are unlikely to
be responsible for NQO1 independent activation of MMC in
tumours in an aerobic environment.
NRH:quinone oxidoreductase 2 (NQO2) has recently been
described as an enzyme of surprises and mysteries (Vella et al,
2005). One of the mysteries assumed of NQO2, in contrast to the
widely studied homologue NQO1, is that it can use neither NADH
nor NADPH as an electron donor. Instead, NQO2 requires the non-
biogenic compound NRH to facilitate enzymatic activity (Knox
and Chen, 2004). In this study, the ability of human recombinant
NQO2 to reduce MMC utilising NADH as an electron donor was
characterised, under conditions similar to those used to char-
acterise NQO1 catalysed reduction of MMC. The inhibition of
enzyme activity by the NQO2 inhibitor quercetin and the NQO1
inhibitor dicoumarol was also investigated. The effect of hrNQO2
bioreductive activation of MMC on NQO2 activity, as measured by
CB1954 reductase activity, was determined. An increased alkyla-
tion of DNA in V79 chinese hamster lung fibroblasts transformed
to overexpress either NQO1 or NQO2 was also observed, compared
to a plasmid transformed control.
MATERIALS AND METHODS
hrNQO1, hrNQO2 (prepared as described in Wu et al (1997)),
bovine serum albumin (BSA), lactose, Tris-HCL, MMC, phos-
phate dibasic, phosphate monobasic, deduced NADH, dico-
umarol, quercetin and ammonium formate were purchased from
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sSigma-Aldrich (Poole, Dorset, UK). Phosphate-buffered saline
(PBS) was purchased from Invitrogen (Paisley, UK) HPLC
grade acetonitrile and methanol were purchased from Fischer
Scientific (Loughborough, UK). CB1954 and NRH were obtained
from Protherics PLC (Cheshire, UK), NQO1 and NQO2 trans-
formed V79 Chinese hamster lung fibroblast cells were also
supplied by Protherics PLC and were generated as described
previously (Knox et al, 2000), Genesis C18 120A 4mm
100 4.6mm HPLC column was purchased from Jones chromato-
graphy (Pontypridd, UK).
Reduction of MMC was carried out in a 100mM potassium
phosphate buffer at 251C at either pH 5.8, 6.5, or 7.4 for 30min.
Initial concentrations were 100mM MMC, 4mM NADH and 162nM
hrNQO1 or 162nM hrNQO2 or 4.2mg/ml of BSA with lactose and
PBS buffer salts. Inhibition studies were carried out at pH 5.8 with
the addition of either 100mM quercetin or 100mM dicoumarol. At
time 0 and 30min, 150ml aliquots from the reaction mixture were
mixed with 450ml acetonitrile, vortex mixed and centrifuged at
12000g for 5min. Supernatant (400ml) was evaporated under
nitrogen and the residue resuspended in 400ml water. Isocratic
HPLC separation of MMC was carried out on a Waters
(Elstree, UK) Alliance 2695 separation module and 2487 dual
wavelength detector with detection at 365nm. Mobile Phase
comprised of 72% 10mM ammonium formate (pH 6.5):28%
acetonitrile at a flow rate of 0.3mlmin
 1. Injection volume was 5ml
with a run time of 10min.
NQO2 kinetic studies were carried out as above at pH 5.8 with a
range of NADH concentrations of 0.25–4mM and 100mM MMC.
Aliquots were removed at 0, 5, 10, 15, 20 and 30min for HPLC
analysis. Mitomycin C concentrations remaining were interpolated
from a standard curve and initial rates were calculated as the initial
slope of a second-order curve of the data.
NQO1 activity assay
The NQO1 activity of cell lysis supernatants was determined by an
adaptation of a previously published method (Gan et al, 2001). The
reaction monitored the reduction of DCIP with and without
dicumarol and the NQO1 activity was taken as the dicumarol-
sensitive fraction. Cell lysate was added to a solution containing
final concentrations of 0.04mM DCIP and 70.01mM dicumarol in
25mM Tris-HCL buffer (pH 7.4). The reaction was initiated by the
addition of NADH to a final concentration of 0.2mM and a
final volume of 300ml. The absorbance at 600nm was measured
at 10s intervals over 2.5min at room temperature, monitored
using a Spectramax 250 spectrophotometer. All reactions were
carried out in 96-well plates and each sample was measured in
triplicate. The concentration of oxidised DCIP remaining at each
time point was calculated from a molar extinction coefficient of
21mlmmol
 1cm
 1. The reaction rate in nanomolar DCIP reduced
per min per mg of total protein was calculated from a plot of A600
against time.
NRH:quinone oxidoreductase 2 activity assay
CB1954 reduction was assayed as previously described (Knox et al,
2000) with minor modifications. V79 lysate (for determination of
cellular NQO2 activity) or an aliquot of hrNQO2 following
incubation of þ/  MMC and þ/  NADH (for determination
of non-competitive inhibition of NQO2 by MMC) were added to a
borosilicate tube containing NRH and CB1954 in PBS to give
final concentrations of 500mM NRH and 100mM CB1954 in a
volume of 1ml at a pH of 7.4. Reactions were incubated at 371C
and 90ml aliquots were removed at 0, 5, 10, 20, 30, 40, 60 and
80min, added to 90ml acetonitrile, vortex mixed and centrifuged at
12000g for 5min. The CB1954 concentration remaining at each
time point was determined by HPLC analysis and inter-
polated from a standard curve. Isocratic HPLC separation of
CB1954 was carried out on a Waters Alliance 2695 separation
module and 2487 dual wavelength detector with detection at
325nm. Reaction mixture (15ml):acetonitrile (50:50) was injected
onto a Genesis C18 120A 4mm 100 4.6mm HPLC column with a
mobile phase of 80% 0.02 M phosphate pH 6:20% methanol at an
isocratic flow of 1mlmin
 1. CB1954 was detected at a wavelength
of 325nM and a retention time of 7min and the concentration
remaining was interpolated from a standard curve. The rate of
CB1954 reductase activity was calculated by the initial velocity per
mg of protein.
DNA alkylation was assessed by modified comet assay as
previously described (McKenna et al, 2003). Exponentially
growing V79 cells transformed to over express either NQO1
(hdt), NQO2 (TH7) or transformed with empty plasmid (f179)
were incubated with 10mM MMC in a final volume of 1ml for 1h at
371C in separate eppendorfs. Following treatment, cells were
centrifuged at 1200g for 3min and washed twice with PBS,
mixed 1/10 with LM aragrose and 75ml aliquots placed on
Trevigen comet assay slides (Gaithersburg, MD, USA) slide.
Once the agarose had set, the slides were irradiated at 10Gy prior
to lysis and subsequent denaturation at pH 13. Cells under-
went horizontal electrophoresis at a constant 300mA and between
15 and 20V for 20min. The slides were washed in deionised
H2O and fixed in 70% EtOH and allowed to dry overnight. The
cells were stained with SYBR green and 3D images acquired
by confocal microscopy. Comets were analysed by Komet 5
software (Wirral, UK)
RESULTS
Reduction of mitomycin C catalysed by hrNQO1 and
hrNQO2
Either hrNQO1 or hrNQO2 alone catalysed the reduction of 100mM
MMC by 3073 and 3575mM, respectively, over 30min incubation
at room temperature and pH 5.8, with NADH as an electron
donor (P¼0.002 and 0.002, respectively, when compared to
buffer, t-test). No reduction of MMC was seen in a solution
containing BSA, lactose and PBS salts under the same conditions
(Figure 1). Reduction of MMC was also catalysed by both hrNQO1
and hrNQO2 enzymes at pH 6.5, but by neither enzyme at
pH 7.4 (Figure 1). NRH:quinone Oxidoreductase 2 activity was
dependent on NADH concentration, with the rate being approxi-
mately 60% of maximum at the lowest NADH concentration
tested (250mM) (data not shown). No reduction of MMC occurred
at any pH with either enzyme in the absence of NADH (data
not shown).
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Figure 1 Reduction of MMC catalysed by hrNQO1 and hrNQO2
compared with BSA:lactose:PBS and no protein controls. At pH 5.8 the
mean MMC reduced in the hrNQO1 reaction (3073.4mM) and the
hrNQO2 (3574.9mM) reaction were significantly less than the MMC
reduced in the no protein control (P¼0.002 and 0.002, respectively, t-
test). Reactions were carried out at pH indicated and room temperature
for 30min using 4mM NADH, 100mM MMC. Data are mean and s.e. of 5
(pH 5.8) or three independent experiments.
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sInhibition of NRH:quinone oxidoreductase 2 catalysed
reduction of mitomycin C
The reduction of MMC catalysed by hrNQO2 was completely
inhibited by 100mM quercetin and partially inhibited by 100mM
dicoumarol when compared to the reaction in the absence of the
inhibitor (Figure 2).
Autodestructive mitomycin C catalysis by NRH:quinone
oxidoreductase 2
NRH:quinone oxidoreductase 2 activity, as measured by reduction
of CB1954 in the presence of NRH, was inhibited by 2972%
following an incubation of hrNQO2 with MMC in the absence of
NADH (pH 5.8, room temperature for 30min) (Figure 3), when
compared to a 30min preincubation of hrNQO2 without MMC.
Preincubation with MMC and NADH resulted in a greater degree
of inhibition (5071% of control).
Comet assay on transformed V79 cells
V79 chinese hamster lung fibroblasts cells transformed to over-
express NQO1 or NQO2 were used to determine the relative degree
of DNA damage caused my MMC. Neither NQO1 nor NQO2
activity was detectable in the empty plasmid transformed cell line
(F179). NRH:quinone oxidoreductase 2 was undetectable in the
NQO1 transformed cell line (hdt) which had a mean NQO1 activity
of 1487729nmolmin
 1mg
 1. NQO1 was undetectable in the
NQO2 transformed cell line (TH7) which had a mean NQO2
activity of 8.272.9nmolmin
 1mg
 1. Following a 1h incubation of
each cell line in 10mM MMC at physiological pH and 371C the
mean Olive tail moment was unchanged compared to untreated
cells in the F179 cells. In contrast both the NQO1 (hdt) and NQO2
(TH7) cell lines had a decreased Olive tail moment following MMC
treatment compared with untreated cells (Figure 4).
DISCUSSION
NRH:quinone oxidoreductase 2 catalyses the reduction of MMC
utilising NADH as an electron donor by a mechanism that is
blocked by the known NQO2 inhibitor quercetin. This reduction
was shown to generate reactive metabolites, which inhibited the
CB1954 reductase activity of NQO2 to a greater degree than
inactivated MMC. Also, there was a lower comet olive tail moment
in NQO2 expressing cells treated with MMC compared with cells
with no detectable NQO2 activity, again indicating the generation
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Figure 2 Reduction of MMC catalysed by hrNQO27quercetin or
dicoumarol. Incubation with 100mM quercetin and hrNQO2 resulted in
inhibition of reduction of MMC (P¼0.002 compared with no inhibitor).
Incubation with 100mM dicoumarol and hrNQO2 resulted in partial
inhibition of reduction of MMC (P¼0.017 compared with no inhibitor).
Reactions were carried out at pH 5.8, room temperature for 30min using
100mM MMC and 4mM NADH. Data are mean and s.e. of three
independent experiments.
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Figure 3 Reduction of CB1954 at 371C, pH 6.3 using NRH as an
electron donor and 200ml aliquots of a 30min preincubation of 16.2nM
hrNQO2 with or without MMC or NADH as described in the text. MMC
added (rhombi) represents the addition of MMC at time 0 of the CB1954
reaction (difference between MMCþNADHþ and MMCþNADH ,
P¼0.0033, 2 Way ANOVA). Lines are second-order curves used to
calculate initial velocity. Data are the mean and s.e. of three independent
experiments.
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Figure 4 Comet olive tail moment of plasmid (F179, white), NQO2
(TH7, grey) or NQO1 (hdt, black) transformed cells following incubation
with or without 10mM MMC. Data represent the mean and s.e. from one of
three independent experiments. ***¼P-value of o0.0001, t-test of mean
compared with untreated control.
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sof DNA-reactive species. This observation is contrary to the
perceived lack of enzymatic function of NQO2, but is not
inconsistent with the literature. Nicotinamide adenine dinucleotide
is used to elute hrNQO2 during affinity chromatography with
cibacron blue as a ligand and hrNQO2 has a Km for NADH three-
to four-fold higher than that of NQO1 (Wu et al, 1997). The 43
carboxy terminal residues of NQO1 which interact with the ADP
section of NADH do not totally restore NADH binding or activity
to NQO2 (Wu et al, 1997) and additional amino-acid differences in
NQO2 compared with NQO1 in the catalytic site are believed to
contribute to the difference in affinity. It has been suggested that
the function of his161 in reduction of NQO1 by NADH prior to
substrate reduction can be achieved by asn161 in NQO2 (Bianchet
et al, 2004).
Despite the low affinity and very low activity of NQO2 for NADH,
human recombinant NQO2 has been reported to have a low
enzymatic activity when high concentrations of NADH are used as a
co-factor and menadione as a substrate (Wu et al, 1997). As a result
of the low affinity of NQO2 for NADH, with most substrates the
concentration of NADH will be the rate-limiting factor. However,
MMC is a poor substrate for NQO1 and substrate concentration may
be the rate-limiting factor for reduction of MMC catalysed by either
NQO1 or NQO2. The original observation of MMC reduction
catalysed by NQO1 used 5.2mg/ml (169nM) purified rat hepatic
NQO1 (Siegel et al, 1992) and this is comparable with the 162nM
hrNQO2 or hrNQO1 used in the present study. Despite the
nonphysiological conditions used in the cell-free systems described
here, NQO2 expression in an isogenic cell model also resulted in
more DNA alkylation, as measured by the comet assay, than was
seen in an NQO1 and NQO2 null background.
Many enzymes have been implicated in the bioreductive
activation of MMC including NQO1, cytochrome C reductase,
cytochrome b5 reductase, xanthine oxidase and xanthine dehy-
drogenase (reviewed by Seow et al (2004)). However, of these
enzymes, only xanthine dehydrogenase functions as a two electron
reductase, the others catalysing a one electron reduction of the
MMC quinone to a semiquinone. In an aerobic environment
semiquinone is spontaneously oxidised to the parent compound
with the production of free radicals. While this is potentially
damaging, it is not believed to be the primary mechanism by which
MMC exerts toxicity. An MMC reductase activity, immunologically
related to NQO1 was identified in NQO1  /  mice and may be
partially attributable to NQO2 (Joseph et al, 1996; Joseph and
Jaiswal, 2000). This activity was inhibited by NQO1 antibodies and
dicoumarol and the published experiment used 1mM NADH, a
level that in the current study was sufficient to catalyse reduction
of MMC (data not shown). A further study suggested this activity
was due to Mr 58000 glucose regulatory protein (GRP58) (Celli and
Jaiswal, 2003). There is no published observation that mouse
GRP58 is immunologically related to NQO1 or that human GRP58
catalyses the reduction of MMC. While this paper was in
preparation it was reported that, in the absence of NRH,
kerotinocytes from the NQO2 /  mouse are less sensitive to
MMC than keratinocytes from wild-type mice (Celli et al, 2006). It
was also observed that CHO cells transformed to overexpress
NQO2 were more sensitive to MMC than wild-type cells and that
recombinant mouse NQO2 with NRH can catalyse the reduction of
MMC with subsequent generation of DNA alkylating species at pH
5.8 in vitro (Celli et al, 2006). These observations are supportive of
the data presented here, but raise the question of whether
endogenous electron donors for NQO2 exist. The NQO2 trans-
formed V79 cell lines used in this study are sensitive to the NQO2
substrate CB1954 only in the presence of added NRH (Knox et al,
2000), indicating the absence of any endogenous NQO2 co-factor
in this system.
The activity described in this study is unlikely to be extrapolated
to other quinone substrates of NQO1 given the unique combina-
tion of low affinity of NQO1 for MMC and the low affinity of NQO2
for MMC and NADH. Mitomycin C is clearly metabolised by NQO2
in the presence of NADH to reactive species that both inhibit
NQO2 and react with DNA to form cross-links. This study offers
no suggestion that NQO2 functions physiologically as an enzyme.
However, these data indicate that NQO2 may contribute to the
bioreductive activation of MMC, particularly in an aerobic
environment.
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